NDC 51662-1375-01 - FAMOTIDINE
This NDC is not currently matched to an FDA NDC product listing in FDA.report, but it is a valid NDC-form code. FDA.report is showing the available DailyMed label context for the product root.
- Product NDC
- 51662-1375
- Requested NDC
- 51662-1375-01
- Package NDCs from labels
- 51662-1375-1, 51662-1375-2, 51662-1375-01
- Manufacturer
- HF Acquisition Co LLC, DBA HealthFirst
- Effective date
- 2022-10-01
- Current FDA listing
- Not matched in FDA.report NDC product tables
DailyMed Labels#
| Label | Manufacturer | Effective date | Type |
|---|---|---|---|
| FAMOTIDINE - HF Acquisition Co LLC, DBA HealthFirst | HF Acquisition Co LLC, DBA HealthFirst | 2022-10-01 | HUMAN PRESCRIPTION DRUG LABEL |
DailyMed Package Descriptions#
| Package NDC | Product | Description | Form | Quantity | Strength | SPL version |
|---|---|---|---|---|---|---|
| 51662-1375-1 | FAMOTIDINE | 2 mL in 1 VIAL, SINGLE-DOSE | INJECTION, SOLUTION | 2 | 3 | |
| 51662-1375-2 | FAMOTIDINE | 1 in 1 POUCH | INJECTION, SOLUTION | 1 | 3 | |
| 51662-1375-2 | FAMOTIDINE | 2 mL in 1 VIAL, SINGLE-DOSE | INJECTION, SOLUTION | 2 | 3 |
DailyMed Dashboard NDC Coverage#
| NDC | Dashboard title | SPL version | Validation | Dashboard ZIP |
|---|---|---|---|---|
| 51662-1375 | FAMOTIDINE INJECTION, SOLUTION [HF ACQUISITION CO LLC, DBA HEALTHFIRST] | 3 | Current NDC, Legacy NDC, 3 package rows | 20221002_9948991d-9405-c7c8-e053-2995a90a60ca.zip |
openFDA label cross-check#
OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.
| Brand | Generic | Manufacturer | SPL set ID | Effective date | Available safety fields | Join |
|---|---|---|---|---|---|---|
| IBUPROFEN AND FAMOTIDINE | IBUPROFEN AND FAMOTIDINE | Camber Pharmaceuticals, Inc. | 7dc158a2-fdfa-4a5f-8c28-0ce5650991db | 2024-07-11 | Boxed warning, Warnings, Adverse reactions | 5QZO15J2Z8 |
| Original strength heartburn prevention | FAMOTIDINE | KROGER COMPANY | ea1c2838-acbd-18e0-e053-2a95a90a3522 | 2024-07-08 | Warnings | 5QZO15J2Z8 |
| Famotidine | FAMOTIDINE | Contract Pharmacal Corp. | 273deac8-c2b0-423f-8662-4f16d91df216 | 2024-07-04 | Warnings, Adverse reactions | 5QZO15J2Z8 |
| FAMOTIDINE | FAMOTIDINE | NuCare Pharmaceuticals,Inc. | fd271deb-c748-bf26-e053-6294a90a11aa | 2024-06-28 | Warnings, Adverse reactions | 5QZO15J2Z8 |
| Famotidine | FAMOTIDINE | NuCare Pharmaceuticals,Inc. | 60cd0973-f74e-2b70-e053-2a91aa0a4361 | 2024-06-06 | Adverse reactions | 5QZO15J2Z8 |
| Famotidine | FAMOTIDINE | A-S Medication Solutions | 0abfc8e6-7fdf-4828-89f4-2202002f8489 | 2024-06-03 | Warnings, Adverse reactions | 5QZO15J2Z8 |
| Famotidine | FAMOTIDINE | A-S Medication Solutions | 75a334ee-48b9-47e7-8225-6e595bed8a74 | 2024-06-03 | Warnings, Adverse reactions | 5QZO15J2Z8 |
| Pepcid | FAMOTIDINE | Bausch Health US LLC | a06502d9-7903-4f37-833e-e5763d502def | 2024-06-01 | Warnings, Adverse reactions | 5QZO15J2Z8 |
| Famotidine | FAMOTIDINE | Rising Pharma Holdings, Inc. | 15b87f7f-1abf-4d8a-bdbe-03bea0021a68 | 2024-05-29 | Warnings, Adverse reactions | 5QZO15J2Z8 |
| Famotidine | FAMOTIDINE | VKT Pharma Private Limited | 1c2cfb3c-eaa0-403f-9589-d706afc06f51 | 2024-05-22 | Warnings | 5QZO15J2Z8 |
| Maximum Strength Acid Reducer | FAMOTIDINE | TARGET CORPORATION | 07a924f1-14cc-4e7d-e063-6394a90ac7f3 | 2024-05-13 | Warnings | 5QZO15J2Z8 |
| IBUPROFEN AND FAMOTIDINE | IBUPROFEN AND FAMOTIDINE | Advanced Rx Pharmacy of Tennessee, LLC | 16c8b0db-37d0-99d9-e063-6394a90ac31b | 2024-04-23 | Boxed warning, Warnings, Adverse reactions | 5QZO15J2Z8 |
| Pepcid Complete | FAMOTIDINE, CALCIUM CARBONATE, AND MAGNESIUM HYDROXIDE | Navajo Manufacturing Company Inc | ac3cd760-4615-117b-e053-2a95a90a8d42 | 2024-04-15 | Warnings | 5QZO15J2Z8 |
| Zantac 360 | FAMOTIDINE | Navajo Manufacturing Company Inc. | e328c59c-baed-0e4e-e053-2995a90ab85c | 2024-04-15 | Warnings | 5QZO15J2Z8 |
| FAMOTIDINE | FAMOTIDINE | Asclemed USA, Inc. | 69bd5340-298b-46ca-83c7-0b5ef233f9c5 | 2024-04-12 | Warnings, Adverse reactions | 5QZO15J2Z8 |
| Famotidine | FAMOTIDINE | Hikma Pharmaceuticals USA Inc. | 1fdf16e5-145d-4c19-a318-fc6c10794b50 | 2024-04-09 | Warnings, Adverse reactions | 1743833 5QZO15J2Z8 |
| famotidine | FAMOTIDINE | CHAIN DRUG MARKETING ASSOCIATION, INC. | 6daf1ebe-b0a2-4413-bf25-3de6eb64b0c6 | 2024-03-27 | Warnings | 5QZO15J2Z8 |
| Famotidine | FAMOTIDINE | Direct_Rx | 138d9ed1-2f8f-d19d-e063-6394a90a695d | 2024-03-13 | Warnings, Adverse reactions | 5QZO15J2Z8 |
| FAMOTIDINE | FAMOTIDINE | NuCare Pharmaceuticals,Inc. | 13168d9e-0697-e5fb-e063-6294a90a69ba | 2024-03-07 | Warnings, Adverse reactions | 5QZO15J2Z8 |
| Maximum Strength Acid Reducer | FAMOTIDINE | TIME CAP LABORATORIES,INC | fe25e1e2-7158-6fe0-e053-6394a90a3bb1 | 2024-03-06 | Warnings | 5QZO15J2Z8 |
Reported adverse events (FAERS/openFDA)#
Adverse event summaries are temporarily unavailable. Other product information remains available.